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Abstract 
Background and Aim. 
There are few data of fibrosis development in chronic hepatitis B (CHB) patients classified as inactive 
carriers. The aim of this study is to determinate the prevalence of significant fibrosis and probable cirrhosis 
measured by FibroScan in real inactive CHB carriers and investigate the relationship with virological, 
epidemiological, and metabolic factors. 
Methods 
Cross-sectional cohort study including CHB inactive carriers. Liver stiffness measurement was performed 
with transient elastography (FibroScan). Significant fibrosis (≥ F2) was defined as stiffness > 7.5 kPa, and 
probable cirrhosis as > 11.8 kPa. Factors associated with significant fibrosis were explored with univariate 
and multivariate adjusted logistic regression analyses. 
Results 
Ninety-six CHB inactive carriers were analyzed. Of them, 24 (25%) had significant fibrosis and 7 (7%) 
probable cirrhosis; mean stiffness was 6.2 ± 2.3 kPa. 
Of them, 24% had metabolic syndrome, with higher FibroScan value than those without (8.4 kPa vs 5.5 kPa, 
P < 0.001). 
Factors associated with significant fibrosis were (odds ratio, 95% confidence interval, P value): central 
obesity (7.1, 1.8–27.9, 0.005), elevated fasting glucose (4.3, 1.3–27.9, 0.036), reduced high-density 
lipoprotein cholesterol (5.2, 1.2–23.6, 0.032) and elevated triglycerides (6.2, 1.4–28.3, 0.019). Factors as age, 
sex, transaminases, hepatitis B virus DNA or genotype were not related with liver fibrosis. 
The presence of metabolic syndrome has a 69% of positive predictive value and 89% of negative predictive 
value for significant fibrosis. 
Conclusion 
Different components of metabolic syndrome are associated with fibrosis development in CHB inactive 
carriers. In the absence of metabolic syndrome, significant fibrosis is uncommon in this population. 
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Chronic hepatitis B (CHB) is a major cause of liver disease and a global health problem 
affecting over 350 million people.[1] Hepatitis B virus (HBV) infection is the most common cause 
of liver cirrhosis and hepatocellular carcinoma.[2] Risk factors for progression to cirrhosis are 
dependent on the patient (older age, male gender, alcohol intake), coinfection status (hepatitis C 
and D, human immunodeficiency virus [HIV]) and laboratory parameters (elevated transaminases, 
high hepatitis B virus DNA [HBV-DNA] levels, positive hepatitis B e antigen [HBeAg] and HBV 
genotype).[3] 
 
Metabolic syndrome (MS) promotes changes in general population, including alterations in 
insulin response and hepatic glucose metabolism, lipid storage and transport, and inflammation. 
Emerging data support a role for lipid and glucose metabolism in fibrosis development and 
hepatocellular carcinogenesis.[4, 5] The prevalence of non-alcoholic fatty liver disease among 
patients with MS is 43–64% (depending on the definition of MS used), in Spanish population.[6] 
In chronic hepatitis C infection, the association with hepatic steatosis is well known;[7] in these 
patients, hepatic steatosis is present in up to 30–70% of patients and is a risk factor for liver 
disease progression[8] and it decreases the response to antiviral therapy, independently of hepatitis 
C genotypes.[9] This association in HBV infection has not been demonstrated, despite several 
studies have focused in this problem last years.[10, 11] Hepatic steatosis and MS in HBV-infected 
patients seem to be less frequent than in the general population and in hepatitis C-infected 
patients.[12, 13] On the other hand, CHB patients with MS were more likely to have advanced 
fibrosis and cirrhosis than those without.[14] Contrary to hepatitis C, in CHB-infected patients, the 
degree of hepatic steatosis and insulin resistance are mainly due to metabolic factors but not 
virological factors.[15] 
 
CHB infection is characterized by a dynamic nature course. Earlier studies assessing fibrosis 
are based on histological samples, in them, patients with low HBV viral load and persistently 
normal transaminases were less represented, and virological factors were determinants in the 
development of hepatic fibrosis. Transient elastography for liver stiffness measurement (LSM) has 
a good correlation with histological studies assessing advanced fibrosis in hepatitis C-infected 
patients as well as it has high sensitivity and specificity to detect histological liver cirrhosis also in 
CHB patients.[16, 17] 
 
Severe fibrosis and cirrhosis are more frequent in HBeAg+ patients than negative and much 
more than in inactive carriers. Some studies have focused on LSM in inactive carriers, defined as 
CHB-infected patients with negative HBeAg, persistently normal alanine aminotransferase (ALT) 
(< 40 IU/L) and HBV-DNA < 10 000 IU/mL,[18, 19] but there are few data with patients 
complying the inactive carrier definition of the European Association for the Study of the Liver 
(EASL), the American Association for the Study of Liver Diseases (AASLD) and the Asian-
Pacific Association for the Study of the Liver (APASL); in them a inactive HBV carrier must have 
HBsAg+, HBeAg-, anti-HBe+, normal ALT/AST levels and HBV-DNA < 2000 IU/mL, 
persistently. 
 
In this study, we aimed to evaluate the LSM with FibroScan in real inactive CHB carriers, 
determinate the prevalence of significant fibrosis and probable cirrhosis in our population, and 




All patients with CHB in clinical follow-up at Complejo Hospitalario Universitario de A 
Coruña (Spain) have been examined. The number of patients with CHB in our institution is close 
to 300 patients. From these, those patients defined as CHB inactive carriers following the criteria 
established by international associations (EASL, AASLD)[20, 21] with at least 2 years of follow-
up were retrospectively included. Persistently, normal ALT were accepted if there were ≥ 3 ALT 
determinations at unspecified intervals during 6–12 months or predefined intervals during ≥ 12-
month periods, respectively, as used previously.[22] 
 
All patients were naïve to antiviral therapy. Patients with an alcohol intake > 30 gr/day, 
coinfected with other hepatototropic viruses or HIV, known hereditary or immune liver diseases or 
history of clinical decompensations of cirrhosis were excluded of the study. 
Clinical, ultrasonographic and laboratory evaluations 
At the clinic visit, smoking, alcohol consumption, drug use, medical and pharmacological 
histories were always recorded. Anthropometric measurement included body height and weight 
and waist circumference (measured at a level midway between the lower rib and the iliac crest). 
Body mass index (BMI) was calculated as weight (Kg) divided by height (m) squared. 
 
Data of the ultrasound examination of the liver carried during the last year before were 
recorded. It was classified as presence (all grades) or absence. 
 
Blood tests were performed after, at least, 8-h fasting. They included coulter, liver and renal 
biochemistry, glucose, insulin and lipids. Normal ALT and AST value was considered < 40 IU/L. 
 
MS was defined according to the criteria of the International Diabetes Federation, modified 
from the National Cholesterol Education Program, Adult Treatment Panel III Guidelines, as three 
or more of: central obesity (waist circumference ≥ 94 cm in men and ≥ 80 cm in women), BMI 
> 30 kg/m2, triglycerides (TG) > 150 mg/dL; reduced high-density lipoprotein cholesterol (HDL-c) 
(< 40 mg/dL in men and < 50 mg/dL in women); blood pressure ≥ 130/85 mmHg; and fasting 
plasma glucose ≥ 100 mg/dL; or receiving treatment for the above metabolic abnormalities.[23] 
 
Enzyme-linked immunosorbent assay (ELISA) commercial kits were used to test HBsAg, 
HBeAg and anti-HBe. HBV genotypes were determined using commercial hybridation assay. 
HBV-DNA levels were measured using real time commercial PCR methods with lower limit of 
detection of 10 IU/mL. 
LSM 
LSM was performed through transient elastography (FibroScan, EchoSense, Paris, France). 
The liver stiffness was expressed in kilopascals (kPa). All studies were carried out by an 
experienced operator (more than 400 examinations). The LSM was optimal only if it had at least 
10 valid shots, success rate > 60% and IQR/LSM < 30%. 
 
Significant fibrosis (≥ F2) was considered if LSM was > 7.5 kPa, and probable cirrhosis 
> 11.8 kPa; previously validated cut-off points in a similar population.[18] 
  
Sample size 
A total of 105 inactive HBV carriers were identified. Of them, 96 (95%) had an optimal LSM 
and were included for analysis. This sample size allows us to determine the prevalence of 
significant and probable fibrosis with a confidence level of 95% and 10% precision. 
 
Moreover, assuming a prevalence of both MS and significant fibrosis around 25% in these 
patients, this study has 80% power, al alpha = 0.05 for a two-sided test, to detect as statistically 
significant OR of 4 or higher for the association of MS and significant fibrosis. 
Statistical analysis 
Statistical analysis was performed by using the Statistical Package for Social Science (spss, 
version 18.0; SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as mean 
(standard deviation) or median (interquartile range) as appropriate, qualitative as number (%). 
Differences between subgroups were analyzed using Fisher's exact test for categorical parameters 
and Mann–Whitney test for continuous variables. Factors associated with significant fibrosis were 
explored using unadjusted and multivariate adjusted logistic regression analyses, including 




A total of 105 inactive HBV carriers were identified. Of them, 96 (95%) had an optimal LSM 
and were included for analysis. The mean age was 46 ± 14 years and 64 (67%) were male. The 
baseline characteristics are shown in Table 1. Of them, 18 patients (19%) were taking 
hypolipidemic therapy, 10 (11%) antihypertensives and 6 (6%) oral antidiabetic agents. 






Yes No P 
 
Yes No P 
 
 
N patients 96 24 (25) 72 (75) 
 
 7 (7) 89 (93) 
 
Age, year 46 ± 14 54 ± 14 43 ± 13 0.001  61 ± 18 45 ± 13 0.004 
Male gender 64 (67) 18 (72) 46 (65) 0.34  5 (71) 59 (66) 0.66 
Current smoker 15 (16) 4 (17) 11 (15) 0.86  2 (29) 13 (15) 0.30 
BMI, kg/m2 25.4 ± 3.6 27.5 ± 4.5 24.7 ± 3 0.001  28.3 ± 4.9 25.2 ± 3.4 0.027 
Waist circumference, cm 85 ± 12 94 ± 12 82 ± 10 < 0.001  96 ± 14 84 ± 11 0.009 
Systolic BP, mmHg 132 ± 17 138 ± 16 129 ± 15 0.006  148 ± 9 130 ± 16 0.002 
Diastolic BP, mmHg 73 ± 12 78 ± 12 71 ± 11 0.004  78 ± 7 72 ± 12 0.01 
Liver stiffness, kPa 6.2 ± 2.3 9.3 ± 2.2 5.1 ± 1.2 < 0.001  12.5 ± 0.8 5.7 ± 1.6 < 0.001 
HBV-DNA undetectable 15 (16) 5 (21) 10 (14) 0.51  2 (29) 13 (15) 0.30 
HBV-DNA, log copies/mL 2 ± 1 1.8 ± 1.2 2.1 ± 1.0 0.16  1.6 ± 1.0 2.1 ± 1.0 0.15 
Genotype Ac 21 (35) 5 (33) 16 (35) 0.89  2 (33) 19 (32) 0.70 
Genotype Dc 28 (47) 6 (48) 22 (47) 0.72  3 (50) 26 (46) 0.66 
Platelet count, × 109/L 226 ± 58 216 ± 42 229 ± 63 0.26  206 ± 52 227 ± 59 0.38 
ALT, IU/L 30 ± 9 31 ± 8 29 ± 9 0.61  29 ± 8 30 ± 9 0.87 
AST, IU/L 26 ± 8 26 ± 7 26 ± 9 0.99  29 ± 10 26 ± 8 0.16 
Albumin, g/dL 4.4 ± 0.6 4.3 ± 0.6 4.4 ± 0.7 0.68  4.3 ± 0.5 4.5 ± 0.7 0.70 
Metabolic syndrome 23 (24) 16 (67) 7 (10) < 0.001  7 (100) 16 (18) < 0.001 
Central obesity 31 (32) 16 (67) 15 (21) 0.002  7 (100) 26 (29) 0.001 
Elevated triglycerides 22 (23) 14 (58) 8 (11) < 0.001  7 (100) 15 (17) < 0.001 
Reduced HDL cholesterol 19 (20) 10 (42) 9 (12) 0.002  4 (57) 15 (17) 0.027 
Hypertension 37 (38) 15 (62) 22 (31) 0.006  7 (100) 30 (34) 0.001 
Elevated fasting glucose 22 (23) 14 (58) 8 (11) < 0.001  6 (86) 16 (18) < 0.001 
Steatosisd 23 (25) 11 (48) 12 (17) 0.007  4 (57) 19 (22) 0.01 
Hypolipidemic therapy 18 (19) 6 (25) 12 (17) 0.02  2 (29) 16 (18) 0.10 
Antihypertensives 10 (11) 3 (12) 7 (10) 0.64  1 (14) 9 (10) 0.46 
Antidiabetics agents 6 (6) 2 (8) 4 (6) 0.78  1 (14) 5 (6) 0.62 
         
 
a Stiffness > 7.5 kPa. 
b Stiffness > 11.8 kPa. 
c N = 60 patients. 
d Steatosis by ultrasound (N = 93 patients). 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; HBV, 
hepatitis B virus; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
 
  
According to the ethnicity, 77 patients (80%) were from Europe (of them, 74 were Spanish), 17 
(18%) from Africa (mainly from Senegal) and 2 (2%) from Asia. 
 
Mean LSM was 6.2 ± 2.3 kPa and 24 cases (25%) had significant fibrosis (> 7.5 kPa) and 7 
(7%) probable cirrhosis (> 11.8 kPa). Table 1 shows qualitative and quantitative differences 
between groups. 
 
Mean HBV-DNA was 2 log copies/mL and 16% (n = 15) of patients showed undetectable 
HBV-DNA viremia. HBV genotype analysis was performed in 81 patients. Finally, information on 
HBV genotypes could be addressed in 60 patients, with the following distribution: A 21 cases 
(35%), B 2 (3%), D 28 (47%), E 4 (7%), F 1 (1%), H 4 (7%). 
 
The prevalence of MS was 24% (23 patients) and it increased with age: was 12% for patients 
of age 20–40, 21% 41–60 and 53% in > 61 years. Those with MS had LSM higher than those 
without 8.4 ± 3.3 kPa versus 5.5 ± 1.4 kPa (P < 0.001). 
 
Mean BMI was 25.4 ± 3.6 kg/m2, and 42 patients (44%) were overweight or obese 
(BMI ≥ 25 kg/m2); mean systolic blood pressure was 132 ± 17 mmHg and diastolic 73 ± 12 mmHg. 
Mean metabolic factors were as follow: fasting glucose 95 ± 21 mg/dL, total cholesterol 
191 ± 36 mg/dL, low-density lipoprotein cholesterol 120 ± 31 mg/dL, HDL-c 56 ± 14 mg/dL, TG 
107 ± 58 mg/dL. 
Factors associated with hepatic fibrosis 
Factors associated with significant fibrosis were explored in multivariate-adjusted logistic 
regression analysis (Table 2). Central obesity (odds ratio [OR] 7.1), elevated fasting glucose (OR 
4.3), low HDL-c (OR 5.2) and elevated TG (OR 6.2) have been associated with significant fibrosis 
(≥ F2). 
Table 2. Multivariate logistic regression analysis on factors associated with significant 
fibrosisa 
Parameter OR 95% CI P 
Age 1.035 0.97–1.11 0.308 
Male gender 1.037 0.23–4.71 0.962 
Central obesity 7.130 1.82–27.87 0.005 
Elevated fasting glucose 4.252 1.25–27.95 0.036 
Reduced HDL cholesterol 5.219 1.15–23.64 0.032 
Elevated triglycerides 6.188 1.36–28.25 0.019 
Hypertension 1.850 0.69–6.74 0.206 
Steatosis 2.130 0.82–3.26 0.160 
Hypolipidemic therapy 1.946 0.78–2.96 0.192 
    
 
a Stiffness > 7.5 kPa. 




Table 3 shows the prevalence of steatosis and significant fibrosis according to number of MS 
criteria. 
Table 3. Prevalence of steatosis (all grades) and significant fibrosis (> 7.5 kPa) according to number 
of MS criteria fulfilled 
Number of MS criteria Prevalence of steatosis (%) Prevalence of significant fibrosis (%) 
0 14.2 9.2 
1 25.3 17.8 
2 38.7 36.8 
3 59.4 57.3 
4 76.6 70.1 
5 91.3 78.4 
≥ 3 to 5 65.2 69.6 
   
 
MS, metabolic syndrome. 
Discussion 
In our study, 7% of inactive HBV carriers had probable cirrhosis and 25% significant fibrosis, 
using the cut-offs proposed by Oliveri et al.[18] When we used the dual cut-off (F ≥ 2 LSM > 9.4 
and ≤ 6.2 kPa) proposed by Vigano et al.,[17] the prevalence of significant fibrosis recognized in 
our population was very similar (20%). To our knowledge, there are few data of LSM in inactive 
carriers according to the proposed definition, and this is the first study analyzing the influence of 
MS in liver fibrosis development. A French study with 58 inactive carriers, found that 9% had 
fibrosis score of > 2 in histological samples.[24] A study in India reported that among inactive 
HBV carriers, 21% had histologically active liver disease, and 13.8% of patients had significant 
hepatic fibrosis.[25] Data of Egyptian inactive carriers had been published recently; in them, 20% 
of patients had fibrosis score ≥ 2 in liver biopsy.[26] 
 
Oliveri et al. reported that in chronic HBV carriers, including patients with HBV-DNA 
> 2000 IU/mL and elevated ALT value, HBV-DNA and ALT were factors associated with fibrosis 
development; metabolic factors did not achieve statistically significance in multivariate 
analysis;[18] but 68 patients were inactive HBV carriers and those with dysmetabolic profile had 
LSM higher than patients without (6.9 kPa vs 4.3 kPa, P < 0.001). In a recent study published by 
Wong et al. with more than 1000 CHB patients, 32% had possible cirrhosis (defined as FibroScan 
> 8.4 kPa); male gender (OR 1.8), age > 40 years (OR 1.8), BMI > 25 Kg/m2 (OR 1.4), albumin 
< 40 g/L (OR 4.2), elevated ALT (OR 2.8) and alkaline phosphatase (OR 2.4) and MS (OR 1.6) 
were associated with possible cirrhosis in multivariate logistic regression; OR 1.1 was reported for 
HBV-DNA > 2 log copies/mL, without statistically significance (P = 0.65), despite mean HBV-
DNA was 5.0 log copies/mL.[14] Our results are in the same line; in our inactive HBV carriers, 
different components of MS are associated with significant fibrosis, without influence of viral 
factors as DNA levels or HBV genotype or hepatic factors as ALT or albumin levels. Of note, only 
a 16% of the study population showed undetectable HBV-DNA levels, therefore, it is not expected 
to show any impact of this parameter on the results obtained. Moreover, the univariate analysis did 
not show any impact of HBV-DNA on the development of fibrosis. Regarding HBV genotype, this 
parameter can be addressed in more than 62% of patients. Lack of amplification (n = 21) or 
undetectable HBV-DNA viremia (n = 15) explain the absence of results for all patients. However, 
since the majority of our patients population are infected with genotypes A or D, the overall 
impact of HBV genotypes in the clinical follow-up of inactive CHB cannot be properly evaluated 
in this study. Moreover, with the current data, the HBV genotype, at least genotypes A or D, does 
not seem to impact in the development of fibrosis. 
 
We hypothesize that CHB infection influences less tan metabolic disturbances in fibrosis 
development of true inactive carriers. We did not find influence of epidemiological factors as 
gender or ethnicity in fibrosis development. In the univariate study, the age seemed to be related 
with significant fibrosis; this association was not demonstrated in the multivariate analysis 
probably because the influence of the age in inactive carriers could be, partly, due to the worsening 
of the metabolic profile. In the multivariate analysis, liver steatosis was not associated with 
significant fibrosis. Since steatosis is very common among patients with MS and all the MS 
criteria are recognized in our study population, it is noteworthy that the prevalence of steatosis in 
our population was > 90%.[27] This might explain the lack of association between significant 
fibrosis and liver steatosis in this study. 
 
Wong et al. also estimated that the prevalence of MS was 11% in CHB and 20% in 
controls;[13] we found a prevalence of 24%. This higher rate is probably due to different reasons, 
mainly the characteristics of the study population; the prevalence of MS in Spanish population is 
15–34%, depending on the criteria used.[6] Therefore, the prevalence in our study for inactive 
HBV carriers is similar with that reported in general population of Western countries.[28] 
 
Transient elastography has been shown to correlate with fibrosis in CHB.[18, 29] Cut-off 
values used for advanced fibrosis (> 7.5 kPa) and for probable cirrhosis (> 11.8 kPa) have a 
positive predictive value of 77% and 86%, respectively, and a negative predictive value of 97% 
and 96%.[18] In general population, LSM remained higher in subjects with MS than in those 
without (6.5 ± 1.6 vs 5.3 ± 1.5 kPa, P < 0.001);[30] in inactive carriers with MS, we found a mean 
FibroScan value higher (8.4 ± 3.3 kPa) than reported for subjects with MS and without CHB. Most 
previous studies of LSM with FibroScan reported a failure rate of 5–8% due to obesity (mainly) 
and other reasons;[31, 32] we excluded 9 cases (5%). 
 
Mechanism connecting steatosis and liver fibrosis are not well known, but are probably related 
to the oxidative stress generated from fat accumulation in hepatocytes, secretion of inflammatory 
cytokines and activation of stellate cells.[33] These processes may contribute to further hepatic 
injury from HBV.[34] However, in the Wong cohort, MS but no steatosis was independently 
associated with liver fibrosis and cirrhosis,[14] similar to our findings. In chronic hepatitis C-
infected patients, steatosis is not associated with severe liver fibrosis, and insulin resistance is the 
major driving force for liver fibrosis;[35] but HBV does not seem to induce insulin resistance.[36] 
 
Our study has a few limitations. Despite that all patients included in the study were 
retrospectively followed at least 2 years to ensure they were inactive HBV carriers, the study has a 
cross-sectional design. Herein, we have analyzed the impact of several parameters 
(epidemiological, clinical, and metabolic) that might be associated with the development of 
fibrosis at a given point in time. However, longitudinal studies are required to properly establish 
those factors influencing the development of fibrosis. This is the case of a recent study published 
by Wong et al.[37] in which they found a low incidence rate of liver fibrosis progression (annual 
incidence rate 0.8%) among HBV inactive carriers. The sample size is relatively small because 
only HBV inactive carriers without other hepatic comorbidities have been included. However, this 
sample size allows us to detect as statistically significant OR of 4 or higher for the association of 
MS and significant fibrosis. Although some associations with lower OR might not be recognized, 
we have demonstrated the association between fibrosis and different metabolic parameters, which 
was mainly the aim of this study. 
 
The assessment of fibrosis was based on transient elastography. Although this methodology 
has been widely validated, it is possible that FibroScan might slightly overestimate fibrosis in our 
study population, since the prevalence of significant fibrosis is relatively low. Furthermore, 5% of 
patients were excluded from analysis due to failed LSM; most of them with central obesity.  
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